PR Newswire

BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA

Written by PR Newswire

SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed Class 1 innovative therapeutic biological product, BR111 for injection. BR111 is an antibody-drug conjugate...

BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA

8 Ways to Protect Yourself When Buying a…

Australians are cooking now more than ev…

The Differences Between the Vast Variety…

Dr Eddy Dona: Thinking about breast enl…

10 Time-Saving Kitchen Hacks Every Home …

The Bulletin Magazine

The Importance Of A 24 Hour Emergency Electrician For Fast And Safe Electrical Response

The Importance Of Vehicle Protection With Bash Plates And Underbody Upgrades

How to Find the Best Off Road Caravans for Australian Adventures

How Rims And Tyres For Sale Sydney Improve Performance, Safety And Driving Confidence

How Huggies Nappies Support Comfort, Absorption And Protection For Babies Of All Ages

How Lighting Shop Perth Stores Help Homeowners Transform Their Spaces With Quality Lighting Solutions

Disability Home Care Services: Empowering Lives Through Quality In-Home Support

Understanding Root Canal Treatment Melbourne and Its Importance for Oral Health

The Most Common Mistakes Businesses Make When Chasing Unpaid Debts

How Traffic Light Systems Improve Road Safety And Support Efficient Traffic Flow

How A Mortgage Broker Near Me Helps Simplify And Strengthen Your Home Loan Journey

Targeting Acne at the Root with Advanced Methods